GlassScriptPhysician profile
Christopher J Gamard
NPI 1215984786
$13,518.17
in general payments reported to CMS, 2019-2025
50 companies · $1,711 in 2025
The $1,711 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,265 · 2020: $1,851 · 2021: $2,857 · 2022: $2,358 · 2023: $1,062 · 2024: $1,415 · 2025: $1,711.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,187 · Education: $0.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,187.27 |
| Education | $0.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,400.35 | 2021-2023 | |
| Novartis Pharmaceuticals Corporation | $1,188.84 | 2019-2025 | |
| Novo Nordisk INC | $953.23 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Takeda Pharmaceuticals U.S.A., INC. | $947.55 | 2019-2025 | Cuvitru, Trintellix, Hyqvia |
| Amgen INC. | $911.40 | 2019-2025 | Evenity, Prolia, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $862.03 | 2021-2025 | |
| Pfizer INC. | $791.63 | 2019-2025 | |
| Lilly USA, LLC | $765.56 | 2019-2025 | Mounjaro, Zepbound, Kisunla |
| Janssen Pharmaceuticals, INC | $717.96 | 2019-2023 | Xarelto |
| Supernus Pharmaceuticals, INC. | $496.21 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $449.94 | 2019-2024 | Xifaxan, Trulance |
| Radius Health, INC. | $414.17 | 2022-2025 | Tymlos |
| Merck Sharp & Dohme LLC | $409.28 | 2019-2023 | Verquvo, Belsomra, Steglujan |
| Astrazeneca Pharmaceuticals LP | $354.79 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Glaxosmithkline, LLC. | $334.59 | 2021-2025 | Shingrix, Arexvy, Trelegy Ellipta |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Gamard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.